Proteomic biomarkers of non-small cell lung cancer patients by Baran, Kamila & Brzeziańska-Lasota, Ewa
REVIEW
419www.journals.viamedica.pl
Address for correspondence: Kamila Baran, Department of Biomedicine and Genetics, Medical University of Lodz, Łódź, Poland; e-mail: kamila.baran@umed.lodz.pl
DOI: 10.5603/ARM.a2021.0089  |  Received: 03.03.2021  |  Copyright © 2021 PTChP  |  ISSN 2451–4934  |  e-ISSN 2543–6031
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as 
long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Kamila Baran , Ewa Brzeziańska-Lasota
Department of Biomedicine and Genetics, Chair of Biology and Medical Microbiology, Medical University of Lodz, Łódź, Poland
Proteomic biomarkers of non-small cell lung cancer patients
Abstract
Lung cancer is a disease with a very low 5-year survival rate (6–13%) worldwide. The most frequently diagnosed histological type 
of this cancer is non-small cell lung cancer (NSCLC). Poor prognosis for lung cancer — including NSCLC — is mainly related to the 
fact that patients are diagnosed in the advanced stages of the disease. The aim of this study is to summarize data that concerns 
new directions of research regarding diagnostic biomarkers that could be used to support the routine diagnosis of this cancer. 
In recent years, proteomic analysis has become an important tool for cancer biology research, complementing genetic analysis. 
Among the numerous methods of proteomic analysis, mass spectrometry techniques enable the extremely accurate qualitative 
and quantitative identification of hundreds of proteins in small volumes of various biological samples. Such analyses may soon 
become the basis of improvement in lung cancer diagnostic procedures. This study presents the latest reports in proteomic 
research concerning the diagnosis of NSCLC. New potential proteomic biomarkers, whose presence indicates the development 
of a neoplastic process at an early stage, are presented. We describe biomarkers whose altered expression levels correlate with 
different stages of cancer. We also present protein biomarkers that help differentiate NSCLC subtypes. In the clinical workup of 
NSCLC patients, it is important not only to make an early diagnosis, but also to monitor the development of the neoplastic disease. 
Considering this fact, we also present examples of biomarkers whose abnormal expression may indicate a high risk of metastasis 
to the lymph nodes. This paper also emphasizes the need to conduct further research that would confirm the usefulness of the 
described biomarkers in clinical practice.
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Introduction
Lung cancer is one of the most commonly 
diagnosed cancers and is also the leading cause of 
cancer-related mortality. In 2018, 2,093,876 new 
cases of lung cancer were diagnosed, which 
accounts for 11.6% of total cases. 1.8 million 
people died (18.4% of total cancer-related deaths) 
[1] with a focus on geographic variability across 
20 world regions. There will be an estimated 
18.1 million new cancer cases (17.0 million 
excluding nonmelanoma skin cancer. This high 
mortality is mainly caused by a late diagnosis in 
patients with advanced-stage cancer. The early 
stage of the disease is characterized by a poor 
clinical manifestation or occurrence of un-
specific symptoms, which makes the diagnostic 
procedure difficult. Therefore, there is an urgent 
need to discover a highly sensitive and specific 
biomarker in order to diagnose non-small cell 
lung cancer (NSCLC) patients at an early stage 
of the disease process.
Proteomic-based lung cancer biomarker search
Proteomic analysis is a powerful tool in the 
global assessment of protein expression and has 
been extensively applied to biomarker discovery 
in clinical diseases [2]. The rapid development of 
mass spectrometry techniques allows to efficient-
ly identify hundreds of differentially expressed 
proteins in small quantities of various biolog-
ical samples [3]. Mass spectrometry identifies 
unknown biomolecules based on their accurate 
mass and fragmentation pattern. However, for 
proteomic studies, this is possible only if a sam-
ple is a simple mixture or has been previously 
divided into simpler parts by high resolution 
separation methods such as two-dimensional 
electrophoresis, protein microarrays, and liquid 
chromatography [4]. Quantitative proteomics 
provides information about relative and absolute 
protein expressions within a sample [5]. 
The most common histological type of lung 
cancer is NSCLC, which accounts for 85% of all 
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cases [6]. Histological subtypes of NSCLC include 
adenocarcinoma (AC) (40%), squamous cell car-
cinoma (SCC) (25%), and many other subtypes 
which occur at a very low frequency [7]. The 
heterogeneity of NSCLC causes difficulty in ap-
propriately diagnosing a patient and subsequently 
selecting an adequate treatment option, which 
differs significantly between subtypes [8]. Due to 
the high prevalence of NSCLC and its diversity, 
there is a need to identify specific biomarkers that 
could be used to support routine diagnosis of this 
cancer. This study presents the latest reports in 
proteomic research concerning new biomarkers 
which may be used in the diagnosis of NSCLC 
(Figure 1).
Protein diagnostic biomarkers detected 
in NSCLC patients
Proteomic studies allowed to identify a great 
number of proteins whose expression was diver-
sified between tumor tissue and adjacent macro-
scopically-unchanged tissue, which constituted 
the control group in this study. As proteomic 
biomarkers of NSCLC, Li et al. [9] listed sele-
nium-binding protein 1 (SELENBP1), carbonic 
anhydrase (CA), heat shock 20KD-like protein, 
transgelin (SM22-alpha), alloalbumin venezia 
(whose expression levels were down-regulated 
in lung cancer tissue), and alpha enolase (which 
was overexpressed). SELENBP1, a member of the 
selenoprotein family, mediates the intracellular 
transport of selenium [10], whose dietary defi-
ciency is associated with an increased incidence 
of epithelial cancers, including lung cancer [11]. 
A progressively decreased expression level of 
SELENBP1 was observed by Zeng et al. [12] in the 
human bronchial epithelial carcinogenic process, 
which indicates its major role in the regulation of 
cancer development and progression. On the ba-
sis of the receiver operating characteristic (ROC) 
curve analysis, the authors revealed the ability of 
the SELENBP1 expression level to distinguish the 
normal bronchial epithelium from preneoplastic 
lesions with a sensitivity and specificity of 80% 
and 79%, respectively. Carbonic anhydrases (CAs) 
are enzymes involved in several fundamental bio-
logical processes including respiration, transport 
of CO2, pH regulation, and ion transport [13]. It 
has been shown that CAs are important mediators 
Figure 1. Proteomic biomarkers of NSCLC patients
AC — adenocarcinoma; AGEL — gelsolin; CA — carbonic anhydrase; CKB — creatine kinase brain-type; eIF-4A1 — eukaryotic translation initiation factor 4A1; ERO1L 
— ERO1-like protein alpha; FN — fibronectin; GSTP1 — glutathione S-transferase P1; hAG-2 — anterior gradient protein 2 homolog; hAG-3 — anterior gradient protein 3; 
Hp — haptoglobin; HSPB1 — heat shock protein beta-1; LBP — lipopolysaccharide binding protein; LRG — leucine-rich alpha-2-glycoprotein; MUC5B — mucin-5B; 
NAPSA — napsin-A; NARS — asparagine-tRNA ligase; NSCLC — non-small cell lung cancer; PEDF — pigment epithelium-derived factor; PRDX1 — peroxiredoxin 
1; SAA — serum amyloid A; SCC — squamous cell carcinoma; SELENBP1 — selenium-binding protein 1; TF — transferrin; TPM3 — tropomyosin alpha-3 chain; 
TTR — transthyretin; VN — vitronectin
Kamila Baran, Ewa Brzeziańska-Lasota, Proteomic biomarkers of NSCLC patients
421www.journals.viamedica.pl
of tumor cell pH by modulating the bicarbonate 
and proton concentrations for cell survival and 
proliferation. A proteomic study by Nigro et al. 
[14] concentrated on two CA isoforms, CAI and 
CAII, revealed a significantly downregulated 
expression level in the tumor tissue compared 
to control tissues, which indicates that these 
proteins could be candidates for use as diagnos-
tic biomarkers in NSCLC patients. SM22-alpha 
is an actin cross-linking protein that is involved 
in calcium interactions and regulates contractile 
properties [15]. It has been found that it may play 
a role in cell differentiation, cell migration, cell 
invasion, and matrix remodeling by stabilizing 
the cytoskeleton through actin binding. How-
ever, the data on the abnormal expression level 
of SM22-alpha in lung cancer is controversial. 
Contrary to the results of Lie et al. [9], another 
proteomic study by Rho et al. [16] revealed an 
upregulated expression level of SM22-alpha in 
lung AC tissues compared to the control tissue.
Searching for biomarkers to diagnose squa-
mous cell lung carcinoma, Zeng et al. [17] as-
sessed the expression level of proteins in differ-
ent stages of disease. The combination of three 
proteins, glutathione S-transferase P1 (GSTP1), 
heat shock protein beta-1 (HSPB1), and creatine 
kinase brain-type (CKB) was found to discrimi-
nate an invasive stage of cancer from the normal 
bronchial epithelium with a sensitivity of 92% 
and a specificity of 91%. Furthermore, they re-
vealed that changes in expression levels of those 
proteins may be used to diagnose a patient with 
preneoplastic lesions with a sensitivity of 96% 
and a specificity of 92%. HSPB1 is a type of small 
Heat Shock Protein (sHSP) which is produced 
in cells by stressors such as hypoxia, UV light 
exposure, and viral agents. There is evidence 
that HSPB1 plays an essential role in cancer as 
it protects from programmed cell death (PCD) 
through interactions with several key regula-
tory proteins. GSTP1 is an enzyme catalyzing 
the detoxification of a variety of electrophilic 
compounds including oxidized lipid, DNA, and 
catechol products, thereby protecting cells from 
bioactive xenobiotics and reactive oxidative 
substances. The down-regulation of GSTP1 en-
hances the level of harmful substances and the 
frequency of gene mutations increasing the risk 
of bronchial epithelial carcinogenesis [17]. The 
study on human bronchial epithelial line cells 
revealed that GSTP1 knockdown increased the 
susceptibility of cell transformation induced by 
benzo(a)pyrene, the main lung carcinogen within 
tobacco smoke. CKB is one of two isoenzymes 
of creatine kinase which are involved in energy 
transduction pathways. It is predominantly ex-
pressed in the brain as well as in the lung, clearly 
in airway epithelial cells. The study by Hara et al. 
[18] demonstrated that CKB expression levels de-
creased in bronchial epithelial cells in the setting 
of cigarette smoke exposure, which is the main 
cause of SCC. According to the results of Zeng et 
al., upregulation of GSTP1 and CKB expression, 
and downregulation of HSPB1 expression may 
indicate the development of squamous cell lung 
carcinoma.
Pleural effusion, which is produced continu-
ously at the parietal pleural level and reabsorbed 
through the lymphatic system, is a significant 
source of NSCLC biomarkers. In a number of dis-
orders, including cancer, it accumulates because 
the rate of fluid formation exceeds the rate of its 
removal. It is rich in proteins, either secreted 
from tumor cells, derived from the circulation, 
or locally released by inflammation. These can 
potentially be used as biomarkers. 
The study by Rodríguez-Piñeiro et al. [19] 
compared the proteome of pleural effusion sam-
ples as well as serum from NSCLC patients to those 
from patients with benign lung diseases such as 
pneumonia or tuberculosis. Their biomarker 
candidates comprise proteins with an increased 
expression in malignant pleural effusions such 
as pigment epithelium-derived factor (PEDF), 
gelsolin, and metalloproteinase inhibitor 2. 
Others studied included S100-A8 and S100-A9, 
although they had a lower expression. PEDF was 
the only protein found with significantly different 
levels both in the pleural effusion and the serum 
from NSCLC patients when compared with be-
nign lung diseases. Recent studies on cell lines 
showed that PEDF affects migration, invasion, 
and motility of NSCLC cells by the regulation 
of thrombospondin 1 expression [20]. Previous 
investigations revealed that increased expression 
levels of PEDF were related to a counteracting 
activity to compensate for increased vascular en-
dothelial growth factor (VEGF) levels [21]. VEGF 
is a strong angiogenic factor that is overexpressed 
during tumorigenesis. Therefore, an increase in 
PEDF would be expected to fight the spread of 
cancer cells.
Blood proteomic analysis may have a great 
advantage over the proteomics performed in 
lung cancer tissue due to the greater availabil-
ity of blood samples. The proteomic study by 
Yang et al. [22] identified three serum candidate 
protein biomarkers for NSCLC: apolipoprotein 
C-I (ApoC-I), haptoglobin alpha-1 chain, and 
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S100A4, which can diagnose NSCLC in patients 
with a sensitivity and specificity of 96.56% and 
94.79%, respectively. ApoC-I is a lipid carrier 
protein and, although previous studies mainly 
focused on lipoprotein metabolism, it has been 
reported that the ApoC-I also regulates many cel-
lular functions such as the promotion of growth 
factor-mediated cell survival and apoptosis [23]. 
It has been demonstrated that ApoC-I has a cer-
tain anticancer effect on tumor cells, as well as 
the ability to decrease the expression of PCNA, 
Ki-67 and Bcl-2 proteins, enhance Bax protein 
expression, and inhibit cell proliferation [24]. 
S100A4, a member of the S100 family of calcium 
binding proteins, influences many biological pro-
cesses including angiogenesis, stimulation of cell 
motility, upregulation of matrix metalloproteinas-
es (MMPs), and modulation of tumor-related tran-
scription factors [25, 26]. In addition, the tumor 
suppressor protein p53 has also been identified 
as a target for the S100A4 protein promoting its 
degradation and may be central for the stimu-
lation of tumor development [27]. As a serum 
potential biomarker for NSCLC patients, Sung 
et al. indicated serum amyloid A (SAA), whose 
expression level was upregulated when compared 
to a control group [28]. Considering that SAA is 
a positive acute phase protein involved in the 
inflammatory response and that lung cancer is 
a chronic inflammatory disease, the elevated 
concentration of this protein is not surprising. 
However, a further study revealed that serum 
SAA expression levels in lung AC were signifi-
cantly higher compared to other diseases of the 
respiratory system such as idiopathic pulmonary 
fibrosis and bronchial asthma, as well as in other 
cancers like stomach and breast cancer. The re-
sults of studies conducted by Urieli-Shoval et al. 
[29] revealed that the production of SAA by the 
alveolar lining epithelium of the lung occurred 
without provoking a continuous systemic acute-
phase response during carcinogenesis. 
In recent years, exosomes have garnered 
considerable attention from researchers due to 
their potential utility as circulating biomarkers 
for cancer. They are small (50–150 nm in diam-
eter), membrane-enclosed particles containing 
nucleic acid and protein cargo, which have been 
implicated in a diverse range of physiological 
functions as well as pathological ones due to their 
capacity to convey molecules from a donor cell 
to a recipient cell. Tumor-derived exosomes have 
been demonstrated to carry the disease-associated 
molecular cargo and modulate the behavior of re-
cipient cells towards a pro-oncogenic phenotype 
[30]. The proteomic studies assessing the profile 
of proteins in exosomes derived from the serum 
of NSCLC patients demonstrated a significantly 
higher expression level of fibronectin [31] and 
lipopolysaccharide binding protein [32]. It was 
shown that these proteins may be good biomark-
ers of NSCLC on the basis of the ROC curve (AUC 
was 0.833 and 0.713, respectively) and could be 
applied to diagnose NSCLC patients.
Subtype-specific tumor markers of blood 
in NSCLC patients
Adenocarcinoma and squamous cell carcino-
ma are the two most common NSCLC subtypes 
and have been shown to differ significantly both 
in terms of their clinical behavior and molecular 
signatures [33–36].
To investigate the expression of tumor-associ-
ated proteins in AC, Li et al. [36] used quantitative 
proteomic analyses which revealed significant 
differences in the expression levels of fibrillin-2, 
ferritin, eukaryotic translation initiation factor 
4A1, annexin A5, mucin-5B (MUC5B), alpha-de-
fensin 1, and anterior gradient protein 3, com-
pared to the control lung tissue. Among these 
proteins, they found that MUC5B may be used 
as a good candidate biomarker in the detection 
of AC. MUC5B is a member of a family of high 
molecular-weight heavily-glycosylated proteins 
which are involved in the processes of epithelial 
differentiation, growth regulation, modulation 
of cell adhesion, cell signaling, and protection of 
the airway against environmental toxins [37, 38]. 
However, there is evidence that mucins also play 
important roles in tumor cell growth, invasion, 
and metastasis in cancer cells. The study by Na-
gashio et al. [39] confirmed that the expression 
level of MUC5B is higher in AC compared to SCC, 
as well as in patients with an advanced stage 
of cancer. Moreover, they noticed a correlation 
between the MUC5B expression level and tumor 
size, nodal status, and pleural invasion. These re-
sults suggest that MUC5B may not only be a useful 
differential diagnostic marker of AC from other 
histological types of lung cancer (especially from 
SCC), but may also serve to be a useful marker 
for more aggressive AC.
Another proteomic study revealed that the 
plasma of AC patients was characterized by 
a higher abundance of transferrin, immunoglob-
ulin heavy chain, and leucine-rich alpha-2-gly-
coprotein [40]. A recent study by Li et al. [41] 
reported that the up-regulated leucine-rich al-
pha-2-glycoprotein expression induced the en-
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hancement of cell proliferation, migration, and 
invasion, and mediated a proangiogenic effect via 
the activation of the transforming growth factor b 
pathway. Chang et al. [42] identified eight differ-
entially expressed proteins between lung AC and 
the control group and these included: fibrinogen 
beta chain, fibrinogen alpha chain, haptoglobin 
(Hp), apolipoprotein A-I, transthyretin, serotrans-
ferrin, Ig alpha-1 chain, and Ig alpha-2 chain. Of 
these, haptoglobin had the highest peak ratio. 
Furthermore, ROC curve analysis revealed that Hp 
may be used as a good biomarker of AC, especially 
for males (AUC was 0.929). The main function of 
Hp is to bind free plasma hemoglobin thus pre-
venting iron loss. However, it was also reported 
that body iron could accumulate in cancer cells 
and promote neoplastic cell growth [43]. It has 
also been shown that Hp has angiogenic [44] and 
antioxidant properties [45] and plays an import-
ant role in cell migration, contributing to cancer 
progression. Furthermore, Hp acts as a potent 
immunoreactive modulator protecting tumors 
against the host’s immunity, which may contrib-
ute to the immune escape of the tumor [46]. The 
study by Abdullah et al. [47] revealed extrahe-
patic expression and synthesis of haptoglobin in 
lung tumors, especially in ACs, when compared 
to healthy lung tissues. The proteomic analysis 
by Kang et al. [49] indicated that a change in the 
HP molecular structure may be related to tum-
origenesis. Hp is a tetrameric protein composed 
of a1, a2, and b chain polypeptides in differing 
combinations, which are connected by disulfide 
bridges. It has been reported that various forms 
of Hp have different abilities to bind hemoglobin 
and different properties regarding inflammatory 
and angiogenic functions [48]. Among the three 
different chains of Hp, a2 and b chains presented 
differences in the expression in AC compared to 
healthy controls. However, only the Hp b chain 
showed a significant difference between lung AC 
and other tumors, such as breast cancer and he-
patocellular cancers, as well as other respiratory 
diseases (tuberculosis, idiopathic pulmonary fi-
brosis, and bronchial asthma) [49]. These studies 
demonstrated the significant role of Hp in the 
development and progression of AC and indicated 
that the Hp b chain could be a potential serum 
biomarker for AC patients.
The comparative analysis of serum proteome 
profiles conducted by Ciereszko et al. [39] re-
vealed a higher abundance of vitronectin (VN), co-
agulation factor XIII, plasminogen, and gelsolin in 
SCC patients compared to AC patients. Recently, 
VN has been reported to be a potent migration-en-
hancing factor and plays an important role in the 
movement of cancer cells to lymphatics and body 
cavities via the interaction with the uPAR receptor 
[50]. It may suggest that VN plays a role in spread-
ing cancer cells in SCC patients. Gelsolin acts as 
a protective protein against apoptosis in NSCLC 
cells, which is mediated through the inactivation 
of PI3K/Akt signaling [51], which may contribute 
to tumor progression.
Stage-specific tumor biomarkers
Based on the Tumor-Node-Metastasis (TNM) 
system, NSCLC patients are classified into dif-
ferent stages of disease (stages IA1, IA2, IA3, IB, 
IIA, IIB, IIIA, IIIB, IIIC, IVA, and IVB) through 
the assessment of primary tumors (T descrip-
tor), regional lymph node (LN) involvement (N 
descriptor), and occurrence of distant metastasis 
(M descriptor) [52]. Depending on the stage of 
NSCLC disease, the 60-month overall survival 
rate significantly decreases from 92–68% in pa-
tients with stage I disease, to less than 10% in 
patients with stage IV disease [53]. Therefore, it 
is extremely important to discover biomarkers in 
the early-stage of NSCLC development.
In an attempt to find new stage-specific tumor 
markers, Deng et al. [54] assessed differential 
protein expression patterns of lung squamous car-
cinoma tissue collected from patients at different 
pathological stages. Among all identified proteins, 
tropomyosin alpha-3 chain (TPM3) demonstrated 
a decrease in the expression level with malignant 
progression from stage I to stage IV, while the 
expression level of peroxiredoxin 1 (PRDX1) was 
significantly increased from stage I to III and had 
a slight decrease at stage IV. To the best of our 
knowledge, this is the only study demonstrating 
the role of TPM3 in NSCLC progression and re-
quires further investigation. PRDX1 is a member 
of the redox-regulating protein family of perox-
iredoxins and has antioxidant activity protecting 
against Reactive Oxygen Species damage, which 
is attributed to its cell survival enhancing func-
tion. The study by Chen et al. [55] on cell lines 
confirmed that PRDX1 I influences cell prolifer-
ation by regulating the cell cycle and enhances 
their metastatic properties by increasing the ex-
pression of bcl-2 and VEGF proteins, contributing 
to tumor progression. 
In order to characterize protein expression re-
flecting clinical stages of individual patients with 
AC, Kawamura et al. [56] performed proteomic 
analysis and identified 81 proteins with signifi-
cantly different expression levels in patients 
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with stage IA of disease compared to patients 
with stage IIIA of disease. Further, proteomic 
analyses by Nishimura et al. [57] demonstrated 
that napsin-A (NAPSA) expression was signifi-
cantly reduced in patients with an advanced 
stage of disease. Furthermore, they found a neg-
ative correlation between the expression level 
of NAPSA and survival time after surgery. The 
study by Nishimura et al. [57] also revealed that 
the anterior gradient protein 2 homolog (hAG-
2) was highly expressed in patients with stage 
IIIA in comparison to those with stage IA. The 
higher expression level of hAG-2 was also related 
to the development of regional lymph node me-
tastasis. This data suggested that the assessment 
of the expression level of these proteins can be 
used to distinguish between early and advanced 
stages of AC.
Metastasis-specific tumor markers
The presence of metastasis in patients with 
NSCLC is the major factor which influences lower 
survival rates. Unfortunately, it is estimated that 
30–50% of NSCLC patients present with metastat-
ic disease at the time of diagnosis [58, 59] as part 
of the Monitoring of Cancer Incidence in Japan 
(MCIJ. A better understanding of the molecular 
mechanism that regulates the development of me-
tastasis is needed; such research will also reveal 
biomarkers predicting the progress of NSCLC.
In terms of determining metastasis-spe-
cific tumor markers, Hsu et al. [60] performed 
a study in lung tissue from AC patients with 
different extents of lymph node involvement. 
Their study indicated that the ERO1-like protein 
alpha (ERO1L) and asparagine-tRNA ligase may 
have a significant impact on the development of 
metastasis in this type of cancer [60]. They also 
suggested that ERO1L overexpression in primary 
sites of early-stage tumor tissue indicated a high 
risk for cancer micrometastasis. Previous studies 
reported that the induction of ERO1L was the key 
adaptive response in the HIF-1-mediated pathway 
under hypoxia that operates to improve VEGF 
secretion, facilitating local tumor progression and 
the formation of distant metastases [61].
The proteomic study by Li et al. performed 
on lung squamous carcinoma tissue indicated 
that 14-3-3 sigma may be a potential lymph 
node metastasis-related biomarker in SSC pa-
tients. The expression of this protein was signifi-
cantly down-regulated in lymph node metastatic 
tumors compared to primary SSC. This protein 
is involved in the negative regulation of cell cy-
cle progression and modulation of cell growth, 
differentiation, and apoptosis [63]. It has been 
shown that reducing the 14-3-3 sigma expression 
by siRNA silencing increased the in-vitro inva-
sive ability of HTB-182 and A549 cells, while 
the enforced expression of ectopic 14-3-3 sigma 
decreased these abilities [62]. This data suggests 
that the downregulation of 14-3-3 sigma expres-
sion in tumor tissues may indicate an increased 
risk of developing lymph node metastases in SCC 
patients. 
The proteomic approach has allowed for 
large-scale studies of protein expression in dif-
ferent tissues and body fluids which have been 
applied to discovering cancer biomarkers. This 
report reviews the major proteomic biomarkers 
which may be used to diagnose the development 
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